Tilray Brands has been a bad buy in recent years, and that could remain the case for the foreseeable future.
Cresco Labs is an underrated and undervalued pot stock that cannabis investors shouldn't overlook.
A company's cash position could help indicate whether a stock offering is on the horizon.
The cannabis lifestyle products company announced mixed results and lowered its full-year outlook.
TLRY earnings call for the period ending March 31, 2024.
If even Tilray can't make money from marijuana, what hope does any company have?
Tilray broke a promise. Now investors are breaking up with the company.
Monday U.S. Featured Earnings Avid Bioservices, Inc. (NASDAQ: CDMO) (Q4) EPS of two ...
Several developments pushed north-of-our-border weed titles higher on the day.